

PEI Pharmacare Bulletin

Issue (2021 - 4) June 14, 2021

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY
(EFFECTIVE DATE: June 28, 2021)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Enoxaparin	Inclunox	30 mg/0.3 ml	Prefilled syringe	02507501	SDZ
	Inclunox	40 mg/0.4 ml	Prefilled syringe	02507528	
	Inclunox	60 mg/0.6 ml	Prefilled syringe	02507536	
	Inclunox	80 mg/0.8 ml	Prefilled syringe	02507544	
	Inclunox	100 mg/1 ml	Prefilled syringe	02507552	
	Inclunox HP	120 mg/0.8 ml	Prefilled syringe	02507560	
	InclunoxHP	150 mg/1 ml	Prefilled syringe	02507579	
Criteria	Open benefit				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Seniors Drug Program, Catastrophic Drug Program				

Enoxaparin	Redesca	30 mg/0.3 ml	Prefilled syringe	02509075	VAL
	Redesca	40 mg/0.4 ml	Prefilled syringe	02509083	
	Redesca	60 mg/0.6 ml	Prefilled syringe	02509091	
	Redesca	80 mg/0.8 ml	Prefilled syringe	02509105	
	Redesca	100 mg/1 ml	Prefilled syringe	02509113	
	Redesca	300 mg/3 ml	Vial	02509121	
	Redesca HP	120 mg/0.8 ml	Prefilled syringe	02509148	
	Redesca HP	150 mg/1 ml	Prefilled syringe	02509156	
	Criteria	Open benefit			
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Seniors Drug Program, Catastrophic Drug Program				

BENEFIT STATUS CHANGE

Effective June 15, 2021, the following currently listed products will move from Special Authorization to Open Benefit, and will no longer require a Special Authorization Request;

- Atropine/diphenoxylate (Lomotil) tablets
- Ezetimibe 10mg tablets
- Montelukast 4mg granules and chew tablets, 5mg chew tablets, 10mg tablets
- Fluconazole 50mg tablets, 100mg tablets, 150mg tablets

- Ketoconazole 200 mg tablets

Please refer to the online Formulary for information on currently listed products and applicable program coverage.

CRITERIA UPDATE

Effective June 28, 2021, the Special Authorization criteria for all currently listed Lovenox products has been updated to include the following note;

- Special Authorization for Lovenox will considered for patients who have used all eligible open benefit enoxaparin products and have had documented serious intolerance or allergic reaction.